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rohn’s disease, ulcerative colitis, and pouchitis are
aused by overly aggressive immune responses to a
ubset of commensal (nonpathogenic) enteric bacteria
n genetically predisposed individuals. Clinical and ex-
erimental studies suggest that the relative balance of
ggressive and protective bacterial species is altered in
hese disorders. Antibiotics can selectively decrease tis-
ue invasion and eliminate aggressive bacterial species
r globally decrease luminal and mucosal bacterial con-
entrations, depending on their spectrum of activity.
lternatively, administration of beneficial bacterial spe-
ies (probiotics), poorly absorbed dietary oligosaccha-
ides (prebiotics), or combined probiotics and prebiotics
synbiotics) can restore a predominance of beneficial
actobacillus and Bifidobacterium species. Current clin-
cal trials do not fulfill evidence-based criteria for using
hese agents in inflammatory bowel diseases (IBD), but
ultiple nonrigorous studies and widespread clinical
xperience suggest that metronidazole and/or cipro-
oxacin can treat Crohn’s colitis and ileocolitis (but not
solated ileal disease), perianal fistulae and pouchitis,
hereas selected probiotic preparations prevent relapse
f quiescent ulcerative colitis and relapsing pouchitis.
hese physiologic approaches offer considerable prom-
se for treating IBD, but must be supported by rigorous
ontrolled therapeutic trials that consider clinical dis-
ase before their widespread clinical acceptance. These
gents likely will become an integral component of
reating IBD in combination with traditional anti-inflam-
atory and immunosuppressive agents.
he chronic idiopathic inflammatory bowel diseases
(IBD) Crohn’s disease and ulcerative colitis appear to
e caused by an overly aggressive cell-mediated immune
esponse to luminal commensal bacteria in genetically
usceptible individuals.1,2 Therefore, it is rational to
onsider therapeutic approaches that eliminate the bac-
erial antigens and adjuvants that constantly drive the
athogenic immune response as a potentially important
omponent of treating IBD, in concert with anti-inflam-
atory and immunosuppressant agents. Although use ofarrow- and broad-spectrum antibiotics, probiotics (ben-
ficial bacteria), prebiotics (dietary components that fos-
er the growth of beneficial bacteria), or the combination
f each of these approaches has considerable logic, un-
ortunately, there is quite limited documentation of ef-
cacy of these agents in properly designed controlled
rials. This clinically oriented review discusses the ratio-
ale, available evidence for the use of antibiotics, probi-
tics, and prebiotics, and their mechanisms of action in
he treatment and prevention of Crohn’s disease, ulcer-
tive colitis, and pouchitis, and attempts to provide an
bjective assessment for the current and potential ther-
peutic role of those approaches. The reader is referred to
everal comprehensive reviews for additional viewpoints
n this controversial topic and more extensive documen-
ation of the literature.3–7
Rationale for Treatment
There is considerable indirect evidence that com-
onents of the complex microecology of the distal ileum
nd colon contribute to the pathogenesis of Crohn’s
isease, ulcerative colitis, and pouchitis (Table 1).1,8–10
uminal bacterial concentrations reach 107 to 108 organ-
sms/g luminal contents in the terminal ileum, 1011/g in
he colon, and 1010–11 in ileal pouches.11 These areas of
ighest anaerobic bacterial populations are involved pref-
rentially in clinical IBD. Moreover, Crohn’s disease
eproducibly responds to diversion of the fecal stream
nd recurs after restoration of bowel continuity or infu-
ion of luminal contents into the bypassed ileum12,13 and
ouchitis does not occur before ileostomy takedown.
hese observations suggest that luminal contents provide
he stimulus for intestinal inflammation. Increased con-
entrations of Enterobacteriaceae and Bacteroides species
dhere to the mucosa of patients with Crohn’s disease and
Abbreviation used in this paper: IL, interleukin.








































































May 2004 PROBIOTICS, ANTIBIOTICS, AND PREBIOTICS IN IBD 1621lcerative colitis14 and invade the mucosa, especially
djacent to ulcers and fistulae.15 Genetic susceptibility in
subset of Crohn’s disease patients is determined by
olymorphisms in NOD 2/CARD 15, which is a cyto-
lasmic receptor for muramyl dipeptide, a specific com-
onent of peptidoglycan in bacterial cell walls.16–18
hese NOD 2/CARD 15 polymorphisms lead to defec-
ive nuclear factor  B activation and appear to result in
nefficient epithelial (and possibly macrophage) clearance
f invasive bacteria19 and perhaps defective defensin pro-
uction and secretion.20 Furthermore, IBD patients ex-
ibit loss of immunologic tolerance to commensal bac-
eria, with both increased T-cell and humoral immune
esponses.21,22 Finally, IBD patients have altered compo-
ition of commensal enteric bacteria with increased Bac-
eroides, adherent/invasive Escherichia coli, Enterococci, and
ecreased Bifidobacterium and Lactobacillus species (Table
).23 Conclusive evidence for a primary role for non-
athogenic enteric bacteria is provided by the lack of
nterocolitis in genetically engineered germ-free (sterile)
ice, rats, and guinea pigs that reproducibly develop
ntestinal inflammation and T helper-1(TH1) or T helper
(TH2) immune responses to cecal bacterial antigens
ithin 1–4 weeks after colonization with commensal gut
acteria.1 Host susceptibility, mediated by genes regu-
ating mucosal immune responses, barrier function, and
able 1. Clinical Evidence for Bacteria in the Pathogenesis o
Evidence Crohn
isease in area of 1 bacterial concentration Termina
mucosal adherence Yes
mucosal invasion Yes
inflammation with bypass, bowel rest Yes
esponse to antibiotics Colon o
rotection by probiotics ?
athogenetic immune response to bacteria Yes
xacerbation by pathogens Yes
, increased; 2, decreased; ?, not studied.











Adherent/invasive, toxigenic E. coli strains
treptobacillus
salivarius






Intestinal Helicobacter speciesicrobial defenses, determine response to commensal
acteria. Wild-type mice and rats exist in harmony with
he same bacteria.24,25 Importantly, commensal enteric
acterial species have selective abilities to induce im-
une-mediated colitis: some are pathogenic, some neu-
ral, and some protective; these selective responses appear
o be host and even regional specific in various mouse
odels.24–26 These results suggest that luminal com-
ensal bacteria provide the antigenic stimulation for
athogenic immune responses in IBD, that genetic pre-
isposition is critical to developing dysregulated im-
une responses to bacteria, and that the relative balance
f beneficial vs. aggressive commensal enteric microflora
etermines mucosal homeostasis vs. inflammation (Table
). This latter concept provides the rationale for selective
herapeutic manipulation of the enteric bacterial popu-
ation by antibiotics, probiotics, and prebiotics.
Antibiotics
Antibiotics are widely recognized to have an es-
ential role in treating the septic complications of IBD,
ncluding the intra-abdominal and perianal abscesses and
stulae of Crohn’s disease, as well as superinfection with
athogens and postoperative wound infection (Table 3).
ost clinicians also use broad-spectrum antibiotics as
djuvant treatment of fulminant colitis and toxic mega-
olon to decrease bacterial translocation. Small bowel
acterial overgrowth is more common than usually per-
sease Ulcerative colitis Pouchitis








able 3. Complications of IBD Requiring Antibiotic
Treatment (With or Without Definitive Therapy)
Intra-abdominal, hepatic, or perianal abscesses, inflammatory
phlegmon
Fistulae (perianal, enteroenteric, enterocolonic, enterocutaneous,
and enterovesicle)
Anal fissures
Small intestinal bacterial overgrowth secondary to strictures, loss
of ileocecal valve, enteroenteric and enterocolonic fistulae
Postoperative infections
Toxic megacolon














































1622 R. BALFOUR SARTOR GASTROENTEROLOGY Vol. 126, No. 6eived,27,28 particularly with loss of the ileocecal valve,
linically significant stricturing with partial small bowel
bstruction and delayed transit, and enterocolonic fistu-
ae. The use of antibiotics in these clinical settings is
mpiric, although uncontrolled trials do show efficacy of
igh-dose (20 mg/kg) metronidazole (see later).29
Antibiotics as primary or adjuvant treatment of active
uminal Crohn’s disease and ulcerative colitis are more
ontroversial. Although the therapeutic rationale for us-
ng antibiotics active against enteric commensal bacteria
s strong, based on the convincing data incriminating
ndogenous luminal bacterial adjuvants and antigens in
he pathogenesis of experimental enterocolitis and IBD,
nd the mechanisms of protection are rational (Table 4),
ontrolled clinical trials supporting use of these agents in
BD patients is meager at best.1,3,30,31 This review briefly
able 4. Mechanisms of Action for Antibiotics in IBD
Decrease luminal and adherent mucosal bacterial concentrations
Selectively eliminate detrimental luminal bacterial subsets (alter
ratio of beneficial to aggressive commensal bacteria)
Decrease tissue invasion, treat microabscesses and secondary
bacterial proliferation adjacent to mucosal ulcers and fistulae
Decrease bacterial translocation and systemic dissemination of
viable bacteria
able 5. Representative Antibiotic Trials in IBD
Author Date Antibiotic
rohn’s disease—primary therapy
Ursing35 1982 Metronidazole 800 mg/d
Sutherland34 1991 Metronidazole 10 or 20 mg/kg
Colombel41 1999 Ciprofloxacin 500 mg 2  day
Arnold42 2002 Ciprofloxacin 500 mg 2  day
Prantera43 1996 Ciprofloxacin 500 mg 2  day 
metronidazole 250 mg 4  day
Greenbloom36 1998 Ciprofloxacin 500 mg 2  day 
metronidazole 250 mg 3  day
Leiper45 2000 Clarithromycin 250 mg 2  day
Steinhardt37 2002 Ciprofloxacin 500 mg 2  day 
metronidazole 250 mg 3  day
rohn’s disease—prevention of postsurgical relapse
Rutgeerts38 1995 Metronidazole 20 mg/kg
Rutgeerts39 1999 Ornidazole 1 g/d
lcerative colitis—primary therapy
Turunen58 1999 Cipro 500 mg 2  day
Mantzaris59 1997 Cipro 500 mg 2  day
Casellas134 1998 Amoxicillin 1 g/
Clavaline acid 250 mg
ouchitis
Madden64 1994 Metronidazole 400 mg 3  day
Shen66 2001 Metronidazole 20 mg/kg or
Cipro 500 mg 2  day
Gionchetti67 1999 Cipro 500 mg 2  day and
Rifaximin 1 g 2  dayummarizes representative published studies (Table 5)
nd attempts to derive broad conclusions based on avail-
ble data. Readers are referred to a more extensive recent
eview of this topic for details of individual trials.3
Crohn’s Disease
Broad-spectrum antibiotics are used to treat
rohn’s disease by experienced investigators,32 but large-
cale rigorously controlled trials have never been per-
ormed.3,30,33 In contrast to these uncontrolled observa-
ions, use of metronidazole (10 or 20 mg/kg/day) is
easonably well documented to be beneficial for primary
r adjunctive therapy of colonic Crohn’s disease, but not
or isolated small intestinal involvement. However, re-
ults for unselected patients are less conclusive. In a
andomized placebo-controlled trial, Sutherland et al.34
eported that treatment with metronidazole for 16 weeks
ignificantly decreased the Crohn’s disease activity index
CDAI) from entry levels in unselected patients but had
o difference in the rates of remission and only 53% of
atients completed the trial. Benefit was dose dependent,
ith 20 mg/kg having greater efficacy than 10 mg/kg. In
multicenter Scandinavian trial, therapeutic response to
etronidazole (800 mg/day or approximately 10 mg/kg)
Duration of treatment Result
16 wk No difference from sulfasalazine
16 wk Superior to placebo (2 CDAI), no
difference in remission
6 wk No difference from mesalamine
6 mo Superior to placebo (2 CDAI)
12 wk No difference from prednisolone
10 wk Uncontrolled, 68% remission
4 wk Uncontrolled, 64% response, 48%
remission
8 wk No improvement over budesonide alone
(33% vs. 38% remission)
12 wk 2 clinical relapse 1 yr vs. placebo
52 wk 2 severe endoscopic relapse vs.
placebo
6 mo Superior to placebo
No benefit vs. placebo
5 days 2 mucosal IL-8 and eicosanoids vs.
placebo
4 wk Superior to placebo
2 wk Both effective, Cipro  metronidazole





































































































May 2004 PROBIOTICS, ANTIBIOTICS, AND PREBIOTICS IN IBD 1623as similar to that of sulfasalazine35 as primary treatment
f Crohn’s disease. In both studies, metronidazole was
ffective for colonic and ileocolonic Crohn’s disease, but
ot for isolated ileitis.34,35 Similarly, the combination of
iprofloxacin and metronidazole is more effective for
rohn’s disease affecting the colon than for isolated small
ntestinal disease.36,37 Rutgeerts et al.38 reported that
igh-dose metronidazole (20 mg/kg/day) begun imme-
iately after resection and continued for 3 months sig-
ificantly decreased the incidence of deep mucosal ulcer-
tion in the neoterminal ileum 6 months after surgery
nd the clinical recurrence rates at 1 year, with a trend
oward protection over the 3 years of observation. Al-
hough this provocative report suggests a role for anaer-
bic luminal bacteria in the postoperative recurrence of
rohn’s disease, toxic doses (20 mg/kg/day) of metroni-
azole were used and treatment was continued only for 3
onths after surgery. Similarly, the related antibiotic
rnidazole used continuously for 1 year significantly
ecreased severe recurrent ulcers in the neoterminal il-
um at 3 and 12 months.39 Although most antibiotics
nly transiently alter luminal bacterial concentrations
wing to proliferation of resistant strains, chronic use of
etronidazole eliminated Bacteroides species in Crohn’s
isease patients for at least 6 months.40 Moreover, the
learance of fecal Bacteroides species correlated with dis-
ase remission. Metronidazole has significant side effects
hat include nausea, anorexia, dysgeusia, dyspepsia, and
eripheral neuropathy that limit use of this agent in
pproximately 20% of patients.
Other single and combination antibiotic regimens can
reat Crohn’s disease effectively. Ciprofloxacin is compa-
able with mesalamine 4 g/day41 and superior to place-
o42 in treating active Crohn’s disease. The primary
utcome of the latter study of patients with moderately
ctive, resistant Crohn’s disease was a decrease in CDAI
ather than the more standard induction of remission.
owever, the mean CDAI level at the end of ciprofloxa-
in treatment was 112, well below the remission cut-off
evel of 150, in contrast to a mean CDAI of 205 in the
lacebo group. The combination of ciprofloxacin and
etronidazole can be effective in Crohn’s colitis,36,43
lthough a retrospective analysis did not show benefit of
he combination over either agent alone, with each ap-
roximately 70% effective.44 Prantera et al.43 reported no
ifference in the outcome of Crohn’s disease patients
reated with ciprofloxacin plus metronidazole (46% re-
ission rate) vs. methylprednisolone (63% remission) for
2 weeks. However, more antibiotic-treated (27%) than
teroid-treated (11%) patients failed therapy. A similar
emission rate was obtained in a 10-week open-labeltudy of combined ciprofloxacin and metronidazole; best
esults were seen in patients concomitantly treated with
orticosteroids and without previous surgery.36 Based on
hese results, Steinhart et al.37 examined the ability of
etronidazole plus ciprofloxacin to improve the effects of
leal-release budesonide in patients with ileal or ileo-
ight colonic Crohn’s disease. The overall response rates
ere no different (38% budesonide  placebo vs. 33%
udesonide  antibiotics), with increased toxicity in the
ntibiotic group (20% vs. 0% withdrawal rates), but
nalysis by disease site showed better antibiotic responses
n the small number of patients (N  33) with colonic
nvolvement (53% remission with antibiotics vs. 25%
emission with placebo, P  0.10). Multiple studies
ith clarithromycin as part of an antimycobacterial reg-
men showed some benefit (see later), but interpretation
as difficult because of the multiple drugs involved.
ncontrolled use of clarithromycin alone induced 64%
esponse and 48% remission rates in resistant Crohn’s
isease patients treated for 4 weeks.45 A pilot study
uggested that rifaximin may have a role in treating
rohn’s disease based on 78% response and 59% remis-
ion rates after 4 months of treatment.46
Several different combinations of antimycobacterial
gents have been used in Crohn’s disease patients to
xplore the hypothesis that mycobacterial species cause
his disorder. The majority of trials using conventional
riple or quadruple antimycobacterial treatments have
een negative,47 but M. paratuberculosis is resistant to
hese traditional agents. Combinations of rifabutin and a
acrolide, usually clarithromycin, with or without clo-
azamine, appear more promising.48–50 These small un-
ontrolled studies report responses ranging from 58% to
3%, with some patients showing mucosal healing and
ustained remissions off anti-inflammatory medications.
owever, up to 20% of patients withdrew from these
rials owing to drug side effects. These studies have been
nconclusive regarding the role of M. paratuberculous ow-
ng to the broad spectra of activity of these antibiotics,
ailure to document selective responses in those patients
ith evidence of M. paratuberculosis infection by either
olymerase chain reaction or serology, and lack of doc-
mentation of clearance of tissue infection in patients
ho respond to treatment. Ongoing, large, controlled
rials in Australia and the United States will help settle
hese issues.
The same antibiotics used to treat luminal Crohn’s
isease have been reported to be beneficial in the treat-
ent of perianal Crohn’s disease.3,51 Unfortunately, no
ontrolled studies have been performed and fistulae tend





























































































1624 R. BALFOUR SARTOR GASTROENTEROLOGY Vol. 126, No. 6he largest studies reported 62% to 83% closure rates to
etronidazole 20 mg/kg.29,52 The combination of met-
onidazole and ciprofloxacin improved perianal fistulae in
of 14 patients (64% response rate) and closure in 3 of
4 (21%) patients.53 Although these uncontrolled results
re not definitive, many clinicians, including this author,
se metronidazole, ciprofloxacin, the combination of
hese agents, or tetracycline as the first-line treatment of
erianal Crohn’s disease in conjunction with surgical
rainage of associated abscesses. 6 Mercaptopurine/aza-
hioprine, infliximab, or tacrolimus can be reserved for
atients not responding to antibiotics. Clinicians must
arn patients about the likelihood of peripheral neurop-
thy with high-dose metronidazole therapy. Paresthesias
re dose and time dependent, with relatively low fre-
uency at 10 mg/kg/day, but an incidence of up to 50%
ith higher doses.54 Paresthesias usually are reversible if
etronidazole is stopped when first detected but can be
rreversible if treatment is continued despite symptoms.
Ulcerative Colitis
Although antibiotics cannot be advocated for
reating ulcerative colitis based on available trials, several
reliminary studies suggest their possible benefit as ad-
uncts to standard anti-inflammatory therapy. Brief to-
ramycin therapy had long-term benefits55,56 and 90% of
atients treated for 18 months with trimethoprim/sulfa-
ethoxazole improved.57 Turunen et al.58 showed a
odest additive effect for ciprofloxacin in the long-term
anagement (6 mo) of ulcerative colitis, particularly in
teroid-treated patients, although short courses of intra-
enous or oral ciprofloxacin were not effective.59,60 How-
ver, the nonabsorbable broad-spectrum antibiotic rifaxi-
in may have some promise,61 consistent with the
bservation that the addition of multiple broad-spectrum
ntibiotics occasionally produce dramatic benefits in pa-
ients with fulminant refractory ulcerative colitis, despite
he absence of demonstrable pathogens.62 A small trial in
lcerative colitis patients showed that 3 intermittent
ourses of rifaximin did not permanently alter the colonic
icrobiota, although resistant Bifidobacterium species
ere found.63
Pouchitis
Overgrowth of commensal bacteria have been pos-
ulated to cause pouchitis in patients with ileal pouch-
nal anastomoses, based on the predictable response to
hort-term treatment with metronidazole and other an-
ibiotics in most patients.64,65 In a controlled trial with
cross-over design, 73% of patients with active pouchi-
is responded to metronidazole vs. a 10% response to
lacebo.64 Both high-dose metronidazole (20 mg/kg) andiprofloxacin (1000 mg/day) treatment for 2 weeks sig-
ificantly decreased objective pouch inflammation, with
etter results and less toxicity seen in the ciprofloxacin-
reated group.66 The combination of ciprofloxacin plus
ifaximin is effective in the majority (89%) of patients
ith refractory pouchitis.67
Lessons From Animal Models
In several rodent models metronidazole or cipro-
oxacin can prevent onset of experimental colitis, but not
everse established disease, whereas broad-spectrum an-
ibiotics both prevent and treat active inflammation.68–72
f interest, metronidazole and ciprofloxacin had selective
rotective effects in different colonic regions,70 suggest-
ng that different bacterial species cause disease in vari-
us colonic segments. Broad-spectrum antibiotics are
ffective in almost all models of acute and chronic colitis
nd ileitis in mice, rats, and guinea pigs.72–75 However,
n human leukocyte antigen (HLA)-B27 transgenic rats
ven broad-spectrum antibiotics have only transient ben-
fit, with recurrence of colitis 1 month after cessation of
reatment; probiotics could prevent this relapse of dis-
ase.76 These results indicate that commensal enteric
acteria have synergistic activities in the induction and
erpetuation of intestinal inflammation. Therapeutic im-
lications of these studies are that most forms of clinical
BD should respond to treatment if the proper combi-
ation of broad-spectrum antibiotics are used, antibiotics
hould be individualized for the region involved (ileum,
ecum, distal colon), and that sequential treatments with
ntibiotics followed by probiotics should be examined, as
as been quite effective in chronic pouchitis.77
Conclusions
These diverse studies strongly implicate enteric
ommensal bacteria in the pathogenesis of Crohn’s dis-
ase and pouchitis, and suggest that both aerobic and
naerobic bacteria contribute to the inflammatory re-
ponse. There is presumptive evidence that metronida-
ole, ciprofloxacin, or the combination of these antibiot-
cs are effective in Crohn’s colitis and ileocolitis, but not
n isolated ileal disease. The author uses antibiotics in
rohn’s colitis, ileocolitis, and perianal fistulae in con-
unction with 5-aminosalicylic acid (5-ASA), corticoste-
oids, and, in appropriate settings, immunosuppressive
gents rather than as single agents. However, use of
ntibiotics as primary therapy of Crohn’s disease is poorly
ocumented, owing to significant defects in the study
esign, high dropout rates, and inadequate numbers of
tudy subjects in the available studies. Equivalency stud-
es are underpowered for definitive results and compari-
































































May 2004 PROBIOTICS, ANTIBIOTICS, AND PREBIOTICS IN IBD 1625alamine, which themselves have questionable efficacy in
rohn’s disease. The use of antibiotics in ulcerative co-
itis currently is not justified based on available studies,
lthough broad-spectrum regimens need to be explored.
lthough proper trials of antibiotics in pouchitis have
ot been conducted, widespread clinical efficacy of most
ntibiotics active against enteric bacteria validate their
se.
Rigorous multicenter studies for optimal antibiotic
egimens in Crohn’s disease (primary therapy and pre-
ention of relapse) need to be conducted using broad-
pectrum agents or combinations of narrow-spectrum
gents. It will be important to carefully consider re-
ponses in subsets of disease using genetic, clinical, or
erologic markers. When used in Crohn’s disease of the
olon, treatment should be for 2–3 months duration and
he patient must be alerted to the risk for peripheral
europathy with sustained use of high doses of metroni-
azole.
Probiotics
Probiotics are viable microorganisms with bene-
cial physiologic or therapeutic activities. Originally
erived from cultured foods, especially milk products,
hese protective bacteria and yeast include the lactic
cid bacilli, Lactobacillus and Bifidobacterium, a non-
athogenic E. coli strain (E. coli Nissle 1917), Sac-
haromyces boulardii, Clostridium butyricum, and Streptococcus
alivarius subspecies thermophiles. More recently, geneti-
ally engineered bacteria that secrete immunosuppres-
ive substances such as interleukin-10 (IL-10) have been
tudied.
Limited clinical trials suggest that selected probiotic
pecies, alone or in combination, can prevent recurrent
ntestinal inflammation and possibly treat active IBD,
able 6. Randomized Double-Blind Trials of Probiotic Agents
Author (date) Probiotic
rohn’s disease
Plein, Hotz (1993)135 Saccharomyces boulardii M
Malchow (1997)93 E. coli Nissle 1917 M
Guslandi (2000)136 S. boulardii M
Prantera (2002)94 Lactobacillus GG Po
lcerative colitis
Kruis (1997)85 E. coli Nissle 1917 M
Rembacken (1999)86 E. coli Nissle 1917 M
Kruis (2001)87 E. coli Nissle 1917 M
Ishikawa (2003)88 Bifidobacteria-fermented milk M
ouchitis
Gionchetti (2000)77 VSL#3 M
Mimura (2002)83 VSL#3 M
Gionchetti (2003)84 VSL#3 Prith best results in pouchitis, and, to a lesser extent,
lcerative colitis (Table 6). These results have generated
onsiderable enthusiasm, as evidenced by more recent
eviews than primary studies.6,78–82
Pouchitis
The most convincing evidence of the clinical ef-
cacy of probiotics in clinical IBD is provided by a small,
rospective, double-blind, placebo-controlled trial show-
ng that daily administration of a combination of 4
actobacillus species, 3 Bifidobacterium species, and 1 S.
alivarium species (VSL 3) for 9 months prevented relapse
f chronic pouchitis after induction of remission by
ntibiotics.77 The relapse rate of VSL 3–treated patients
as 15% (3 of 20 patients) vs. 100% in the placebo-
reated group (N  20). Moreover, every patient relapsed
ithin 3 months of stopping VSL 3. These results have
een replicated83 and extended by decreasing the fre-
uency of pouchitis by prospectively administering VSL
beginning at the time of pouch closure.84 In this
rophylactic study, 2 of 20 patients (10%) receiving 1
acket of VSL 3 containing 900 billion bacteria/day for
year developed pouchitis vs. 40% of placebo-treated
atients. Moreover, median stool frequency in subjects
ot developing pouchitis was significantly less (5 vs. 8
tools/day) in VSL 3 vs. placebo-treated patients.84
Ulcerative Colitis
Several probiotic preparations show promise in
lcerative colitis, although results are not as convincing
s in pouchitis. E. coli Nissle 1917 was reported to be as
ffective as low-dose 5-ASA in preventing relapse of
lcerative colitis.85–87 A small study showed that admin-
stration of Bifidobacteria-fermented milk decreased the
ate of relapse of ulcerative colitis to 3 of 11 treated
D
Clinical situation Result
nance of remission 2 diarrhea vs. placebo
nance of remission 2 relapse vs. placebo
nance of remission (probiotic 
lamine vs. mesalamine alone)
2 relapse vs. mesalamine
alone
erative prevention No benefit
in remission Equal to mesalamine (1.6 g)
in remission Equal to mesalamine
in remission Equal to mesalamine
in remission Superior to placebo
in remission chronic pouchitis Superior to placebo
in remission chronic pouchitis Superior to placebo





























































































1626 R. BALFOUR SARTOR GASTROENTEROLOGY Vol. 126, No. 6ubjects vs. 9 of 10 controls.88 Uncontrolled pilot studies
ave indicated that VSL 3 maintained remission of ul-
erative colitis in 75% of patients over 12 months89 and
educed active inflammation in 87% of ambulatory pa-
ients with mild to moderate disease.90 Similarly, uncon-
rolled administration of the nonpathogenic yeast S. bou-
ardii for 4 weeks induced a clinical remission in 17 of 24
71%) of patients with mild to moderate ulcerative co-
itis.91 A provocative study by Borody et al.92 addressed
he hypothesis that ulcerative colitis patients have ab-
ormal enteric bacteria. They showed reversal of refrac-
ory ulcerative colitis in 6 patients who were repopulated
ith fecal enemas from normal patients.
Crohn’s Disease
Results of probiotic trials in Crohn’s disease are
ixed. Malchow93 found that E. coli Nissle was superior
o placebo in preventing relapse of Crohn’s disease after
nduction of remission by standard medical therapy, but
rantera et al.94 reported no benefit of Lactobacillus GG
dministered for 1 year in preventing postoperative re-
apse of symptoms or endoscopic lesions in the neoter-
inal ileum. However, a pilot study of Lactobacillus GG
eported benefit in pediatric patients with active Crohn’s
isease with successful tapering of steroids in 3 of 4
atients.95
Lessons From Animal Models
Animal models are useful to study optimal treat-
ent protocols and to evaluate mechanisms by which
robiotic microbial agents mediate their protective ef-
ects. A number of Lactobacillus and Bifidobacterium spe-
ies attenuate experimental colitis in IL-10 knockout
ice, including native murine L. reuteri,96 VSL 3,97 L.
lantarum,98 L. salivarius, and B. infantis.99 Host back-
round appears to be important because L. plantarum but
ot Lactobacillus GG can prevent colitis in HLA B27
ransgenic rats.76 This study and many others indicate
hat various probiotic species have different protective
ffects in selected hosts and inflammatory conditions. Of
ote, probiotic bacteria were able to prevent recurrence
f colitis in HLA B27 transgenic rats after induction of
emission with broad-spectrum antibiotics, but could
ot by themselves induce a remission of established
isease.76 These results suggest that probiotic agents may
e more effective in preventing relapse of disease than in
nducing remission and that sequential administration of
ntibiotics to induce a remission followed by probiotics
o maintain quiescent disease may be an effective long-
erm synergistic approach to clinical management of IBD
atients. This possibility is supported by clinical trials in
efractory pouchitis patients.77 Finally, a novel approacho probiotic therapy is suggested by prevention and
reatment of colitis in 2 murine models by daily admin-
stration of Lactococcus lactis, engineered to secrete recom-
inant IL-10.100 This approach is now in pilot trials in
BD patients.
Mechanisms of Protection by Probiotics
Multiple mechanisms of action have been sug-
ested to explain the protective effects of probiotic
gents in intestinal inflammation (Table 7). These can be
lassified broadly as suppression of growth or epithelial
inding/invasion by pathogenic bacteria, improved epi-
helial barrier function, or immunoregulatory activities.
detailed description of these mechanisms is beyond the
cope of this clinically oriented review, but several recent
xamples of each category are provided. Bifidobacterium
nfantis suppressed growth of Bacteroides vulgatus,101 an
rganism associated with IBD and experimental coli-
is.24,102 Similarly, Bifidobacterium-fermented milk de-
reased fecal B. vulgatus concentrations in ulcerative co-
itis.88 Suppression of the growth and function of enteric
athogenic bacteria has been attributed to decreased
uminal pH via production of short chain fatty acids,
ecretion of bactericidal proteins, and prevention of ep-
thelial adherence. E. coli Nissle 1917 inhibited both in
itro epithelial adhesion and invasion by an adherent/
nvasive E. coli strain isolated from Crohn’s disease pa-
ients.103 Parallel results using L. plantarum and en-
eroadherent E. coli suggested that up-regulation of
UC-2, a primary intestinal mucin glycoprotein, by this
robiotic bacterial species prevented pathogenic bacterial
dherence.104 In addition, S. thermophilus and L. acidophi-
us prevented entry of enteroinvasive E. coli by rho-
ependent and -independent mechanisms.105 These re-
ults were confirmed by Mattar et al.,106 who postulated
hat stimulation of mucins would decrease bacterial
able 7. Mechanisms of Action of Probiotics
Inhibit pathogenic enteric bacteria
Decrease luminal pH
Secrete bacteriocidal proteins
Colonization resistance (occupy ecologic niche)
Block epithelial binding—induction of MUC 2
Inhibit epithelial invasion—Rho-dependent and -independent
pathways
Improve epithelial and mucosal barrier function




Induce IL-10, transforming growth factor  expression and
secretion
Stimulate secretory immunoglobulin A production






























































































May 2004 PROBIOTICS, ANTIBIOTICS, AND PREBIOTICS IN IBD 1627ranslocation. Indeed, oral or rectal administration of L.
lantarum to mice treated with trinitrobenzene sulfonic
cid decreased the translocation of commensal enteric
acteria to mesenteric lymph nodes and spleens.107 Sim-
larly, Lactobacillus GG decreased E. coli translocation in
abbits.108 Although the mechanisms are not clear, mu-
osal permeability was decreased by administration of L.
euteri or VSL 3 to IL-10/ mice.96,97 A number of
tudies showed that several probiotic agents can induce
rotective cytokines, including IL-10 and transforming
rowth factor , and suppress proinflammatory cyto-
ines, such as tumor necrosis factor, in the mucosa of
atients with pouchitis and Crohn’s disease,109–111 in
L-10/ mice99 and in isolated splenocytes.112 Obvi-
usly, induction of IL-10 is not the sole mechanism of
rotection because multiple probiotic agents prevent and
reat colitis in IL-10–deficient mice.96–99
Recent data indicate that nonviable components of
robiotics can mediate their beneficial effects. Both se-
reted proteins and DNA of VSL 3 can block nuclear
actor  B and p38 mitogen-activated protein kinase
ctivation and prevent apoptosis of epithelial cells.113,114
nterestingly, different effects are seen with DNA from
ifferent bacterial species within the VSL 3 mixture.113
onmethylated DNA (CpG) from VSL 3 and a randomly
elected E. coli strain can suppress experimental colitis in
everal models; this suppression is mediated through
LR 9, which binds CpG.115
Conclusions
Several probiotic preparations have promise in
reventing relapse of chronic pouchitis and ulcerative
olitis, and possibly in the treatment of mild to moder-
tely active ulcerative colitis and prevention of postop-
rative pouchitis. Results in Crohn’s disease are not yet
lear owing to conflicting results and a paucity of trials.
his approach is quite appealing because of a lack of
oxicity and to the enthusiasm of patients wishing to use
atural physiologic approaches to treating IBD. Animal
odels suggest that optimal results may be achieved by
rophylactic use of probiotics after induction of remis-
ion by antibiotics, which can suppress detrimental bac-
erial populations. Thus, the combinations of antibiotics
nd probiotics can restore the normal predominance of
eneficial enteric bacteria. The optimal composition,
ose, and length of probiotic treatment in various IBD
linical settings need to be determined by large, well-
esigned, placebo-controlled, prospective trials. In addi-
ion, it is clear that all Lactobacillus and Bifidobacterium
pecies are not equally beneficial, each may have individ-
al mechanisms of action, and host characteristics may
etermine which probiotic species and even strain maye optimal in a given setting. Thus, one cannot consider
robiotics as a generic form of therapy. Therefore, results
ust be interpreted accordingly and trials designed to
onsider phenotypic and genetic subsets of patients.
Prebiotics
Prebiotics are dietary substances, usually nondi-
ested carbohydrates, that stimulate the growth and
etabolism of protective commensal enteric bacte-
ia.116,117 Lactosucrose, fructo-oligosaccharides, inulin,
ran, psyllium, and germinated barley extracts foster the
rowth of Lactobacillus and Bifidobacterium species and
timulate production of short chain fatty acids, especially
utyrate.118,119 Thus, these prebiotic food additives have
he potential to restore the deranged balance of beneficial
s. aggressive commensal bacterial species in the distal
leum of IBD patients by several mechanisms. These
hysiologic substances stimulate growth of protective
actic acid bacilli, which secondarily suppress detrimen-
al species by decreasing the luminal pH and by inducing
olonization resistance, blocking epithelial attachment,
nd secretion of bactericidal substances. In addition,
ncreased substrate availability and enhanced numbers of
etabolically active Lactobacilli and Bifidobacteria in-
rease bacterial fermentation, with resultant butyrate
roduction that improves epithelial barrier function. The
et result of prebiotic administration is functionally
quivalent to administering probiotic bacteria. Although
his is an extremely attractive concept for treating intes-
inal inflammation, experimental support for these nu-
riceuticals is even less extensive than that for probiotics.
Human IBD
Several small controlled studies of prebiotics have
een reported in ulcerative colitis patients, but none have
een performed in Crohn’s disease. Germinated barley
oodstuff, a glutamine- and hemicellulose-rich extract of
pent beer-brewing constituents, stimulates growth of
ifidobacterium and Eubacterium species and production of
utyrate and other short chain fatty acids.120 Four-week
dministration of 20–30 g of germinated barley extracts
o patients with mild to moderate ulcerative colitis de-
reased clinical and endoscopic evidence of inflammation
n both a pilot and a small placebo-controlled trial.121,122
his treatment increased fecal concentrations of Bi-
dobacterium species and Eubacterium limosum. A longer-
erm (24 wk) open-label study of 21 patients reached
imilar conclusions.119 Psyllium, long used by clinicians
o maintain stool consistency in both constipation and
iarrhea, is a form of prebiotic by virtue of its ability to































































































1628 R. BALFOUR SARTOR GASTROENTEROLOGY Vol. 126, No. 6ion of psyllium was superior to placebo in decreasing
ymptoms of patients with inactive ulcerative colitis,
ith a consistent increase in fecal Bifidobacterium con-
entrations, and decreased free water in the stool.123
Lessons From Rodent Models
A number of prebiotic preparations have been
hown to inhibit experimental colitis and to increase
uminal concentrations of lactic acid bacteria. Madsen et
l.96 showed that lactulose enhanced growth of endoge-
ous Lactobacilli and attenuated colitis in IL-10–defi-
ient mice. Similarly, feeding inulin124 or germinated
arley extracts125–127 inhibited dextran sodium sulfate
DSS)-induced colitis and increased luminal concentra-
ions of short chain fatty acids, including butyrate, Lac-
obacilli, and Bifidobacteria. Kanauchi et al.127 reported a
ecrease in serum IL-6 levels and mucosal signal trans-
ucers and activators of transcription factor (STAT-2)
nd nuclear factor  B activity after germinated barley
oodstuff treatment of mice with DSS-induced colitis.
herbut et al.128 reported that fructo-oligosaccharides,
hich promote the growth of lactic acid bacteria and
ncrease production of butyrate and lactate, decreased
rinitrobenzene sulfonic acid–induced colitis in rats. Ad-
inistration of high doses (1011 colony forming units/
ay) of intragastric lactic acid bacteria or intracolonic
utyrate and lactate had similar protective effects, sug-
esting that the beneficial effects of prebiotics were
ediated by induction of short chain fatty acids and
rowth of luminal probiotic bacteria. However, Moreau
t al.129 reported no benefit of fructo-oligosaccharides but
protective effect of type 3 resistant starch in the DSS rat
olitis model. Similarly, galacto-oligosaccharides had no
rotective effect in trinitrobenzene sulfonic acid–treated
ats, although colonic Bifidobacteria concentrations were
ncreased.130 Hoentjen et al.131 showed that the combi-
ation of inulin and fructo-oligosaccharides significantly
ecreased gross and histologic inflammation and cecal
L-1 concentrations while increasing cecal transforming
rowth factor  secretion in HLA-B27 transgenic rats.
hese results suggest that the combination of several
rebiotic compounds may be effective, analogous to
ocktails of various probiotic bacteria. Studies in gnoto-
iotic rats colonized with human enteric bacteria com-
ared dietary administration of inulin, fructo-oligosac-
haride, or the combination of both prebiotic agents.132
ructo-oligosaccharides stimulated growth of Bifidobac-
erium and Lactobacillus species more effectively, whereas
nulin induced higher luminal concentrations of bu-
yrate. Thus, combinations of prebiotics may have addi-
ive effects owing to multiple mechanisms of action.
imilar to probiotic bacterial species, each prebiotic sub-tance has unique characteristics and therapeutic appli-
ations. Finally, nondigestible oligosaccharides sup-
ressed in vitro growth of C. difficile, independent of the
ctivities of Bifidobacterium,133 suggesting that prebiotics
ay be beneficial in treating bacterial toxin–induced
olitis.
Conclusions
Prebiotics offer an exciting potential treatment
or IBD patients, with the strong theoretic rationale of
timulating growth of endogenous protective lactic acid
acilli and production of cytoprotective butyrate. This
pproach promises to be safe, physiologic, and cost ef-
ective, and therefore could be considered for long-term
rophylactic use and possibly applied to high-risk indi-
iduals or those with subclinical disease. However, stud-
es of this topic are just beginning and considerable data
eed to be generated to provide clinical proof of efficacy
n different clinical situations before these agents can be
pplied to widespread clinical use. Because each agent
as unique properties, comparative studies of various
rebiotic compounds and combinations of agents, vari-
us doses, and duration of treatment need to be per-
ormed. Certain compounds (i.e., lactulose) have impor-
ant side effects, including diarrhea and gas formation,
hich may limit their use in IBD patients. In addition,
onsideration should be given to altering the patient’s
iet because increasing the amount of dietary fiber and
atural dietary oligosaccharides while decreasing refined
arbohydrates similarly may restore a healthy balance of
rotective vs. detrimental enteric bacterial species. Fi-
ally, the interesting approach of combining probiotic
nd prebiotic agents (synbiotics) has considerable appeal
nd may decrease the required dose, duration, or fre-
uency of probiotic administration, thereby decreasing
osts and improving compliance (adherence) to treat-
ent.
Conclusions and Future Directions
Although the rationale for therapeutic manipula-
ion of the luminal microbiota in IBD is uncontested,
urrent data for therapeutic efficacy do not withstand
igorous scrutiny or fulfill current evidence-based stan-
ards for using antibiotics, probiotics, and prebiotics in
he treatment of IBD. Clinical trials consistently have
een underpowered to show equivalency or superiority,
any have design flaws that preclude definitive results,
r use outcomes, such as mean CDAI, that do not con-
orm with widely accepted criteria for disease response or
emission. Thus, enthusiasm outstrips scientific support













































































May 2004 PROBIOTICS, ANTIBIOTICS, AND PREBIOTICS IN IBD 1629ent data do not strongly support use of these agents,
ost trials and clinical experience suggest therapeutic
enefit of antibiotics, especially metronidazole, cipro-
oxacin, the combination of these 2 agents, and, possi-
ly, clarithromycin, in the adjunctive treatment of active
rohn’s disease involving the colon and possibly in the
ostoperative neoterminal ileum (Table 8). Likewise,
etronidazole, ciprofloxacin, and rifaximin effectively
reat pouchitis. Currently approved antibiotics are not
ffective in active ulcerative colitis, although broad-spec-
rum, nonabsorbable agents show promise in early trials.
xisting probiotic agents, either alone (E. coli Nissle) or
n combination (VSL 3), can prevent relapse of ulcerative
olitis and chronic relapsing pouchitis, respectively. The
atter combination of 8 probiotic species appears prom-
sing in prevention of pouchitis with prophylactic use
fter ileal pouch–anal anastomosis and in the treatment
f active ulcerative colitis. Prebiotics have great potential
ut have not been adequately tested yet in IBD to reach
alid conclusions. Large, well-designed, multicenter,
ontrolled, clinical trials need to be organized and con-
ucted to examine the possible indications listed in
able 8 to determine whether these agents will have a
lace in the IBD treatment armamentarium.
Although current clinical support is weak, therapeutic
anipulation of luminal microecology has considerable
otential as a physiologic nontoxic approach to treating
nd, perhaps even more importantly, maintaining med-
cally or surgically induced remission and ultimately
reventing onset of disease in high-risk individuals. As
dditional susceptibility genes are defined for both
rohn’s disease and ulcerative colitis, genetic testing will
e used widely to screen family members and possibly
he general population. Nontoxic means to treat disease
t a preclinical stage or to prevent onset of inflammation
n high-risk individuals will need to be developed. Pro-
iotics and/or prebiotics may be optimal agents for pro-
hylactic use because of their physiologic nature and lack
f obvious toxicity. Similarly, these approaches may be
ighly amenable for life-long use to prevent recurrence in
atients with IBD once a remission occurs.
Optimal application of antibiotics, probiotics, and
rebiotics will depend on a clear understanding of which
able 8. Current and Potential Uses of Antibiotics, Probiotics
Reasonable evidence
ntibiotics CD colitis, ileocolitis, (active), pouchitis Postop
robiotics Chronic pouchitis (prevention of relapse) Pouch
UC (prevention of relapse)
rebiotics None None
D, Crohn’s disease; UC, ulcerative colitis.ndividual agent is indicated for a defined patient subset.
urrent data suggest that metronidazole and ciprofloxa-
in are not effective for treatment of Crohn’s ileitis, but
an benefit Crohn’s patients with colonic involvement. It
ay be that different bacterial populations are responsi-
le for disease in various intestinal regions, as suggested
y selectively monoassociated IL-10–deficient mice.25
urthermore, different bacteria may have dominant ef-
ects in different genetic backgrounds. Thus, optimal use
f various antibiotics, probiotics, and prebiotics may
epend on identifying patient subsets by genetic, phe-
otypic, stool microbiologic, serologic, or T-cell immune
esponse criteria. Finally, antibiotics may be used opti-
ally to eliminate certain aggressive (or pathogenic)
nteric bacterial populations, followed by exogenous pro-
iotics or prebiotics to fill the open ecologic niche,
hereby permanently altering the balance of enteric mi-
robiota for long-term efficacy. The concept of synbiotics
simultaneous use of probiotics and prebiotics) has con-
iderable conceptual appeal and may decrease the dose,
requency, or duration of probiotic administration,
hereby minimizing the expense of treatment. Similarly,
oncomitant use of antibiotics, probiotics, and/or prebi-
tics in combination with immunosuppressives to block
athogenic immune responses, growth factors to accel-
rate mucosal healing and to optimize mucosal barrier
unction, and granulocyte-macrophage colony-stimulat-
ng factor to potentiate bacterial killing and clearance
rovide the best hope for altering the insidious progres-
ion of idiopathic IBD.
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